...
首页> 外文期刊>World journal of gastroenterology : >Pneumocystis jiroveci pneumonia and pneumomediastinum in an anti-TNFalpha naive patient with ulcerative colitis.
【24h】

Pneumocystis jiroveci pneumonia and pneumomediastinum in an anti-TNFalpha naive patient with ulcerative colitis.

机译:抗TNFα幼稚型溃疡性结肠炎患者的肺炎支原体肺炎和纵隔肺炎。

获取原文
获取原文并翻译 | 示例

摘要

We report the case of a 21-year-old man who was noted to have pneumomediastinum during an admission for an acute flare of ulcerative colitis. At that time, he was on maintenance treatment with azathioprine at a dose of 1.25 mg/kg per day, and had not received supplementary steroids for 9 mo. He had never received anti-tumor necrosis factor (TNF)alpha therapy. Shortly after apparently effective treatment with intravenous steroids and an increased dose of azathioprine, he developed worsening colitic and new respiratory symptoms, and was diagnosed with Pneumocystis jiroveci (carinii) pneumonia (PCP). Pneumomediastinum is rare in immunocompetent hosts, but is a recognized complication of PCP in human immunodeficiency virus (HIV) patients, although our patient's HIV test was negative. Treatment of PCP with co-trimoxazole resulted in resolution of both respiratory and gastrointestinal symptoms, without the need to increase the steroid dose. There is increasing vigilance for opportunistic infections in patients with inflammatory bowel disease following the advent of anti-TNFalpha therapy. This case emphasizes the importance of considering the possibility of such infections in all patients with inflammatory bowel disease, irrespective of the immunosuppressants they receive, and highlights the potential of steroid-responsive opportunistic infections to mimic worsening colitic symptoms in patients with ulcerative colitis.
机译:我们报告了一名21岁男子的病例,该男子在入院时因溃疡性结肠炎急性发作而患有肺纵隔。当时,他正在接受每天1.25 mg / kg硫唑嘌呤的维持治疗,并且连续9个月未接受补充类固醇治疗。他从未接受过抗肿瘤坏死因子(TNF)α治疗。在静脉注射类固醇和增加剂量的硫唑嘌呤明显有效治疗后不久,他出现了恶化的大肠菌病和新的呼吸道症状,并被诊断出患有罗氏肺孢子虫(carinii)肺炎(PCP)。肺纵隔炎在具有免疫功能的宿主中很少见,但在人类免疫缺陷病毒(HIV)患者中是PCP的公认并发症,尽管我们患者的HIV检测结果为阴性。用复方新诺明治疗PCP可以缓解呼吸道症状和胃肠道症状,而无需增加类固醇剂量。随着抗TNFα疗法的出现,对炎症性肠病患者的机会感染越来越提高警惕。该病例强调了考虑所有炎症性肠病患者感染的可能性的重要性,而不论他们接受何种免疫抑制剂,并强调了类固醇反应性机会感染模仿溃疡性结肠炎患者恶化的结肠病症状的潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号